t******g
发帖数: 462 | 1 Amylin Pharmaceuticals Inc., Eli Lilly & Co. and Alkermes Inc. dropped in
early trading after they were rebuffed a second time in a bid to gain
approval of a once-weekly version of the diabetes drug Byetta.
The Food and Drug Administration “blindsided” the companies late yesterday
by calling for a study assessing the heart risks for the new drug Bydureon,
said Phil Nadeau, an analyst with Cowen & Co. in New York.
The FDA restricted the use last month of GlaxoSmithKline Plc’s diabetes
drug Avandi... 阅读全帖 |
|
b*****p
发帖数: 9649 | 2 by http://www.guancha.cn/xiaopengcai
星期五传出来Ariad Pharmaceuticals($ARIA)公司内部董事会开始内斗。目前这家公司
的最大股东是萨瑞莎资本公司（Sarissa Capital）拥有6.9%的股份。自从这家维权对
冲基金公司（Activist Hedge Fund）入主这家公司，市场上就开始有心理准备这场即
将到来震荡。萨瑞莎资本公司的创始人叫Alex Denner，今年45岁，是真正的高富帅啊
。这人麻省理工大学本科毕业，耶鲁大学生物医学工程专业博士，博士毕业后在华尔街
摩根斯坦利（Morgan Stanley）和维京全球投资公司（Viking Global Investors）做
医药和生物科技基金经理，后来拜入卡尔·伊卡恩（Carl Icahn）门下统管医药和生物
科技对冲基金，成为卡尔·伊卡恩门生。这人非常内行专业，很懂得分析生物医药公司
的内在价值并把这种价值体现在商业价值上。2012年羽翼丰满脱离卡尔集团自创萨瑞莎
对冲基金公司。
我在前面2月8日文章“大鱼吃小鱼，小鱼吃虾米”中有提到卡尔·伊卡恩是一个传奇投
资... 阅读全帖 |
|
|
D******9
发帖数: 2665 | 4 Bydureon Gains EU Approval
Print Share
By: Zacks Equity Research
June 22, 2011 |Comments: 0
Recommended this article (0)
LLY | ALKS | AMLN | NVO
Amylin Pharmaceuticals, Inc. (AMLN) and its partners, Eli Lilly and Company
(LLY), and Alkermes, Inc. (ALKS), recently received a boost with the
European Commission granting marketing authorization to Bydureon (exenatide
once-weekly) for the treatment of type II diabetes.
Bydureon is the first once-weekly treatment to gain approval for type II
diabetes.... 阅读全帖 |
|
v**********m
发帖数: 5516 | 5 You guys now are able to listen to these web-castings now. Enjoy it!
http://jpmorgan.metameetings.com/webcasts/healthcare11/ondemand
individual Company Presentations
A
Abbott
Abiomed Inc. (available to Feb. 5)
Ablynx N.V.
Accretive Health Inc.
Accuray Inc.
Acorda Therapeutics, Inc. (available to Feb. 11)
Actelion Ltd
Aetna Inc. (available to Feb. 8)
Affymetrix Inc.
Agilent Technologies Inc.
Albany Molecular Research Inc.
Alere Inc (available to Feb. 11)
Alexion Pharmaceuticals, Inc. (not availab... 阅读全帖 |
|
v**********m
发帖数: 5516 | 6 You guys now are able to listen to these web-castings now. Enjoy it!
http://jpmorgan.metameetings.com/webcasts/healthcare11/ondemand
individual Company Presentations
A
Abbott
Abiomed Inc. (available to Feb. 5)
Ablynx N.V.
Accretive Health Inc.
Accuray Inc.
Acorda Therapeutics, Inc. (available to Feb. 11)
Actelion Ltd
Aetna Inc. (available to Feb. 8)
Affymetrix Inc.
Agilent Technologies Inc.
Albany Molecular Research Inc.
Alere Inc (available to Feb. 11)
Alexion Pharmaceuticals, Inc. (not availab... 阅读全帖 |
|
y*****l
发帖数: 5997 | 7 22 Hot Drugs Facing FDA Approval in 2012
By Adam Feuerstein 11/29/11 - 08:55 AM EST
BOSTON (TheStreet) -- Here's your first look at the biotech and
pharmaceutical companies with pending FDA drug approval decisions in 2012.
The calendar on the following pages captures nearly two-dozen U.S.
regulatory events -- FDA drug approvals and advisory panels -- expected
between December 2011 and July 2012. As every savvy biotech investor and
trader knows, the volatility in biotech and drug stocks ramps sig... 阅读全帖 |
|
l****z
发帖数: 29846 | 8 WASHINGTON—Combining aerobic exercise and resistance training lowered blood
-sugar levels in people with Type 2 diabetes, a new study has found.
The same improvement in glycemic levels wasn't seen among patients who
performed aerobic exercise or resistance training alone, according to the
study, which will be published in this week's Journal of the American
Medical Association.
Patients who walked and lifted weights also lost more fat and trimmed their
waistlines more than people who did just on... 阅读全帖 |
|
e*****7
发帖数: 31 | 9 BMY-IMCL deal gets done and may be in a higher price around 65-70. IMCL
jumped 20 to 65 from yesterday's close of 45.
Here are the list of comapnies on speculation list of future dating game:
Amylin/Eli Lilly (Byetta); OSI/Genentech (Tarceva); Biogen/Genentech (
Rituxan); Genzyme/BioMarin (Aldurazyme); Vertex/JNJ (Telapravir); Human
Genome Sciences/Novartis & GSK (Albuferon & LymphoSTAT); Regeneron/Sanofi (
VEGF-TRAP) ; Onyx/Bayer (Nexavaar); Idenix/Novartis (various compounds) ;
Momenta/Novarti |
|
o*****t
发帖数: 339 | 10 This Week's Key Events: Another Big Week for Earnings
By Joseph Hargett, Senior Equities Analyst
Here is a brief list of some of the key events for the upcoming week.
All earnings dates listed below are tentative and subject to change.
Please check with each company's respective Web site for official
reporting dates.
Monday
On the economic front, March's leading indicators report arrives on
Monday. Amylin Pharmaceuticals Inc. (AMLN), Citigroup Inc. (C), Eli
Lilly & Co. (LLY), Halliburton Company |
|
O**I
发帖数: 776 | 11 【 以下文字转载自 pennystock 俱乐部 】
发信人: OSCI (TX), 信区: pennystock
标 题: FDA Drug Approvals in 2011
发信站: BBS 未名空间站 (Sat Jan 8 17:29:50 2011, 美东)
http://www.thestreet.com/story/10944267/1/biotech-calendar-fda-
BOSTON (TheStreet) -- An early Christmas present for biotech investors: The
first (overstuffed) FDA drug approval calendar of 2011.
More from Adam Feuerstein
Dendreon Bringing Provenge to EuropeBiotech Stock Mailbag: Best Stocks to
Watch in '11Merck Beats Vertex to FDA Hep C Filing
Market Activity
... 阅读全帖 |
|
C*G
发帖数: 7495 | 12 青蛙学园当时的一条是，不是内行，尽量避免生科类股票。赌fda比ER还难，但是判决
前后还有机会的。举个例子，去年那个Amylin要补点材料，判决后抢了点，在业内大牛
银杏博士的指示下，蹭了顿巴费就走了的说。生科大牛我老还推荐不停的买的铁牛大侠。
hiahia |
|
w****r
发帖数: 245 | 13 大侠，分类都分好了，求神签
# Basic Materials, Agricultural Chemicals
AGU Agrium Inc.
AVD American Vanguard Corp.
CAGC China Agritech Inc.
CF CF Industries Holdings, Inc.
CGA China Green Agriculture, Inc.
CMP Compass Minerals International
COIN Converted Organics Inc.
IPI Intrepid Potash, Inc.
MON Monsanto Co.
MOS Mosaic Co.
NOEC New Oriental Energy & Chemical
POT Potas... 阅读全帖 |
|
e*****u
发帖数: 67 | 14 Can anybody suggest which I should buy?
http://oh.tellapal.com/a/clk/g7wn
Here is a list of Icahn Capital’s portfolio (its top holdings):
Company Name Ticker
MOTOROLA SOLUTIONS MSI
BIOGEN BIIB
CHESAPEAKE ENERGY CHK
SANOFI AVENTIS SNY
LIONS GATE LGF
AMYLIN PHARMA AMLN
MENTOR GRAPHICS MENT
HAIN CELESTIAL HAIN
LAWSON LWSN
TAKE-TWO INTERACTIVE TTWO
REGENERON PHARMA REGN
CYBERONICS CYBX
MATTEL ... 阅读全帖 |
|
r***s
发帖数: 1805 | 15 批了. 小玩了一个 bull spread, 估计挣不了几个钱.
FDA approves Bydureon from Amylin, Alkermes, Bloomberg says |
|
r***s
发帖数: 1805 | 16 批了. 小玩了一个 bull spread, 估计挣不了几个钱.
FDA approves Bydureon from Amylin, Alkermes, Bloomberg says |
|
e*****u
发帖数: 67 | 17 Can anybody suggest which I should buy?
http://oh.tellapal.com/a/clk/g7wn
Here is a list of Icahn Capital’s portfolio (its top holdings):
Company Name Ticker
MOTOROLA SOLUTIONS MSI
BIOGEN BIIB
CHESAPEAKE ENERGY CHK
SANOFI AVENTIS SNY
LIONS GATE LGF
AMYLIN PHARMA AMLN
MENTOR GRAPHICS MENT
HAIN CELESTIAL HAIN
LAWSON LWSN
TAKE-TWO INTERACTIVE TTWO
REGENERON PHARMA REGN
CYBERONICS CYBX
MATTEL ... 阅读全帖 |
|
e*****u
发帖数: 67 | 18 Can anybody suggest which I should buy?
http://oh.tellapal.com/a/clk/g7wn
Here is a list of Icahn Capital’s portfolio (its top holdings):
Company Name Ticker
MOTOROLA SOLUTIONS MSI
BIOGEN BIIB
CHESAPEAKE ENERGY CHK
SANOFI AVENTIS SNY
LIONS GATE LGF
AMYLIN PHARMA AMLN
MENTOR GRAPHICS MENT
HAIN CELESTIAL HAIN
LAWSON LWSN
TAKE-TWO INTERACTIVE TTWO
REGENERON PHARMA REGN
CYBERONICS CYBX
MATTEL ... 阅读全帖 |
|
g*******s
发帖数: 2054 | 19 这跟公司也有关系， 凭不是简单的东西部关系吧。 一般大公司（东部多一些）给的工资高， 但是股票给的少。 SD学生物的大部份在小公司里， 工资可能是低一些（-10%），股票拿的多些。 所以如果运气好的， 公司一上市，又有Promising的新药出来， 你一年的option卖掉大概会有年工资的50%-100% 左右， 远远超过在大公司一年的总体收入。
看看历史， 随便选了几个公司，在这些公司工作的同胞们如果去的时间得当，那还是
发了一把的：
Amylin
Agouron
Aurora
Neurocrine
Idec
illumina
Isis
。。。。。。。。。。。
当然小公司的Job肯定不如大公司稳定， 上面提到的这些公司如今要么被买走了， 要么解雇了大部分的员工。可是， Life Goes On， 你可以去下个公司寻找你的梦或者趟在海滩上晒太阳了。
还有一点， 我们这里一年花在Utility上的费用远远低于东部吧， 每年的Property Tax(如果你买了房子）也比东部少很多（而两边的房价差别不大） |
|
|
S***A
发帖数: 40 | 21 Bio-Pharma Conference 2013
Paving the Path to Success
Date: June 8th, 2013, 8:00am – 4:45pm
Location: Hilton, San Diego/Del Mar
Website: http://sabpa.org/html/
Registration: https://www.123signup.com/register?id=bdkys
$30 for early birds (by May 22), $50 before end of June 2, $80 for onsite
registration, students and postdocs $10 off (The fees include parking at the
hotel, program brochure, continental breakfast, coffee break, and lunch).
Online registration closes on June 2.
Or... 阅读全帖 |
|
m******j
发帖数: 5079 | 22 发信人: SABPA (美中生物技术与医药协会), 信区: SanDiego
标 题: SABPA BioPharma Conference June 8
发信站: BBS 未名空间站 (Fri May 31 02:16:38 2013, 美东)
Date: June 8th, 2013, 8:00am – 4:45pm
Location: Hilton, San Diego/Del Mar
Directions: Go to the bottom of page
Registration: https://www.123signup.com/register?id=bdkys
$30 for early birds (by June 2), $50 before end of June 5, $80 for onsite
registration, students and postdocs $10 off (The fees include parking at the
hotel, program brochure, continental breakfast, coffee... 阅读全帖 |
|
S***A
发帖数: 40 | 23 Date: June 8th, 2013, 8:00am – 4:45pm
Location: Hilton, San Diego/Del Mar
Directions: Go to the bottom of page
Registration: https://www.123signup.com/register?id=bdkys
$30 for early birds (by June 2), $50 before end of June 5, $80 for onsite
registration, students and postdocs $10 off (The fees include parking at the
hotel, program brochure, continental breakfast, coffee break, and lunch).
Online registration closes on June 2.
Organizer: Sino-American Biomedical & Pharmaceutical Professionals
... 阅读全帖 |
|
e*****u
发帖数: 67 | 24 Can anybody suggest which I should buy?
http://oh.tellapal.com/a/clk/g7wn
Here is a list of Icahn Capital’s portfolio (its top holdings):
Company Name Ticker
MOTOROLA SOLUTIONS MSI
BIOGEN BIIB
CHESAPEAKE ENERGY CHK
SANOFI AVENTIS SNY
LIONS GATE LGF
AMYLIN PHARMA AMLN
MENTOR GRAPHICS MENT
HAIN CELESTIAL HAIN
LAWSON LWSN
TAKE-TWO INTERACTIVE TTWO
REGENERON PHARMA REGN
CYBERONICS CYBX
MATTEL MAT
C... 阅读全帖 |
|
w***u
发帖数: 17713 | 25 糖尿病药也还是有参照天然产物的，Amylin前些年被批准的糖尿病药byetta就是一例，
见于沙漠里的某种巨蜥唾液,该动物特耐饿耐渴，代谢不同寻常。当然生产提纯上不可
能杀蜥蜴取口水。这类轶事是很多的。 |
|
h*******g
发帖数: 23 | 26 糖尿病是世界性问题，中国也是2型糖尿病的重灾区，对于糖尿病药物的研发也是成为
目前和以后研发的重点方向。
随着欧美国家的经济环境，大药厂纷纷关闭国外的研发中心，而中国凭借其人力资本的
优势，吸引了那些大药厂，纷纷来中国建立研发中心。而且各个巨头也通过收购等手段
把研发方向延伸到糖尿病方向，如AZ和BMS合资收购了Amylin。
所以这样的一些建设，也是带动了国内的医药研发的速度。
所以如果想回国的大牛们，可以先观望起来了。未雨绸缪。
以前总说国外的月亮更圆，可是现实如今真是如此吗？
如果您想了解国内最新的医药研发的行情可以联系Henry.愿意成为你们回国的桥梁。
h*******[email protected] |
|
S***A
发帖数: 40 | 27 【 以下文字转载自 SanDiego 讨论区 】
发信人: SABPA (美中生物技术与医药协会), 信区: SanDiego
标 题: [Early Birds End On May 22] SABPA BioPharma Conference on June 8, 2013
发信站: BBS 未名空间站 (Fri May 17 19:50:10 2013, 美东)
Bio-Pharma Conference 2013
Paving the Path to Success
Date: June 8th, 2013, 8:00am – 4:45pm
Location: Hilton, San Diego/Del Mar
Website: http://sabpa.org/html/
Registration: https://www.123signup.com/register?id=bdkys
$30 for early birds (by May 22), $50 before end of June 2, $80 for onsite
regi... 阅读全帖 |
|
S***A
发帖数: 40 | 28 【 以下文字转载自 SanDiego 讨论区 】
发信人: SABPA (美中生物技术与医药协会), 信区: SanDiego
标 题: SABPA BioPharma Conference June 8
发信站: BBS 未名空间站 (Fri May 31 02:16:38 2013, 美东)
Date: June 8th, 2013, 8:00am – 4:45pm
Location: Hilton, San Diego/Del Mar
Directions: Go to the bottom of page
Registration: https://www.123signup.com/register?id=bdkys
$30 for early birds (by June 2), $50 before end of June 5, $80 for onsite
registration, students and postdocs $10 off (The fees include parking at the
hotel, program brochure, cont... 阅读全帖 |
|
q***y
发帖数: 87 | 29 【 以下文字转载自 JobHunting 讨论区 】
发信人: chinesegogo (gogo), 信区: JobHunting
标 题: Job Opportunity
发信站: BBS 未名空间站 (Thu Apr 3 23:53:45 2008)
Company in Southern CA. Email me if interested. c*********[email protected]
Please put "Research" in the subject line.
*****************************************************************************
RESPONSIBILITIES: Candidate will support controlled/sustained-release
formulation development and manufacturing process development studies for
protein/peptide drugs in Amylins |
|
S***A
发帖数: 40 | 30 【 以下文字转载自 SanDiego 讨论区 】
发信人: SABPA (美中生物技术与医药协会), 信区: SanDiego
标 题: SABPA BioPharma Conference June 8
发信站: BBS 未名空间站 (Fri May 31 02:16:38 2013, 美东)
Date: June 8th, 2013, 8:00am – 4:45pm
Location: Hilton, San Diego/Del Mar
Directions: Go to the bottom of page
Registration: https://www.123signup.com/register?id=bdkys
$30 for early birds (by June 2), $50 before end of June 5, $80 for onsite
registration, students and postdocs $10 off (The fees include parking at the
hotel, program brochure, cont... 阅读全帖 |
|
c*********o
发帖数: 1734 | 31 email me to c*********[email protected] with resume in WORD format. Please place "
Analytical" in the subject line.
*****************************************************************************
RESPONSIBILITIES: Develop and validate analytical methods. Supervise/audit
analytical development and testing activities at contract laboratories for
Amylin projects. Provide expertise in field of development to other
department members and project teams. Write analytical methods and research
reports. Assist i |
|
c*********o
发帖数: 1734 | 32 Company in Southern CA. Email me if interested. c*********[email protected]
Please put "Research" in the subject line.
*****************************************************************************
RESPONSIBILITIES: Candidate will support controlled/sustained-release
formulation development and manufacturing process development studies for
protein/peptide drugs in Amylins pipeline; plan and schedule development
work according to departments and company's timetables and establish short
and long term g |
|
t*******h
发帖数: 69 | 33 下个月有一个onsite,不知道版上有没有人了解这家公司?谢谢
update: 刚看了recruiter发给我的面试流程，都是一些director级别的。。。请问这
种情况下主要问technical 还是behavior 问题啊，紧张阿，偶得第一个onsite。。。
。 |
|
|
|
w******y
发帖数: 8040 | 36 你应该更放松了吧
万一没拿到奥佛， 心里说不去更好
你看我多好 |
|
|
b*******g
发帖数: 513 | 38 Too many, amylin, branches of big companies, like pfizer, novartis.And I was
told there were hundreds of biotech companies. |
|
Y******Y
发帖数: 8753 | 39 irvine也就他是一哥了。 :)
现在经济不好知道大家都比较deperate,就压价了。不过据我所知，就是年景好的时候，他们也是同行里面pay的低的。但是没有现在这么低。
而且主要是因为附近没有什么太多的竞争吧。amgen给的多但是也是香饽饽，能进去的
人不多，amylin估计是同类水平的，pfizer已经不招人。他们用不着提高待遇就能找到
很多愿意来的人。 |
|
f*r
发帖数: 408 | 40 【 以下文字转载自 Stock 讨论区 】
发信人: outwest (havefun), 信区: Stock
标 题: Events and ERs for Week 4/19 - 4/23
发信站: BBS 未名空间站 (Sun Apr 18 18:46:16 2010, 美东)
This Week's Key Events: Another Big Week for Earnings
By Joseph Hargett, Senior Equities Analyst
Here is a brief list of some of the key events for the upcoming week.
All earnings dates listed below are tentative and subject to change.
Please check with each company's respective Web site for official
reporting dates.
Monday
On the economic front, March's... 阅读全帖 |
|
t*******o
发帖数: 1464 | 41 http://www.thestreet.com/story/10766153/1/alkermes-vivitrol-gets-speedy-fda-review.html
Alkermes(ALKS) will hear from U.S. drug regulators by Oct. 12 about an
approval decision for the company's drug to treat patients addicted to
opioid painkillers, the company said.
October is shaping up to be busy month for Alkermes. On Oct. 22, the FDA is
also expected to issue an approval decision for Bydureon, the company's long
-acting diabetes drug which is partnered with Amylin Pharmaceuticals and Eli
Li... 阅读全帖 |
|
N***i
发帖数: 2063 | 42 http://www.zacks.com/stock/news/37221/Pharma+and+Biotech+Industry+Outlook+-+July+2010
By: Zacks Equity Research
July 20, 2010 | Comments: 0
Recommended this article (2)
ABT | JNJ | PFE | MRK | RHHBY | BMY | SNY | MYL | LLY | GSK | ACL | GILD |
BIIB | AMLN
Print Share
The pharmaceutical industry has witnessed major changes over the past few
quarters, with performance being affected by factors like sluggish
prescription trends, intensifying generic competition and limited late-stage
catalysts. ... 阅读全帖 |
|
K********g
发帖数: 9389 | 43 Type 2 Diabetes
Ninety to 95 percent of the estimated 246 million adults worldwide who
suffer from diabetes have type 2 diabetes.(1) Despite the introduction of
new medications over the last decade, many people with diabetes are unable
to control their blood sugar.(2) An extended-release formulation of
exenatide may provide a new treatment option for patients with type 2
diabetes.
New treatment paradigm: BYDUREON™ (exenatide extended-release for
injectable suspension) is an extended-rele... 阅读全帖 |
|
O**I
发帖数: 776 | 44 http://www.thestreet.com/story/10944267/1/biotech-calendar-fda-
BOSTON (TheStreet) -- An early Christmas present for biotech investors: The
first (overstuffed) FDA drug approval calendar of 2011.
More from Adam Feuerstein
Dendreon Bringing Provenge to EuropeBiotech Stock Mailbag: Best Stocks to
Watch in '11Merck Beats Vertex to FDA Hep C Filing
Market Activity
Orexigen Therapeutics Inc.| OREX
DOWN
Dendreon Corporation| DNDN
InterMune Inc.| ITMN
For easy reference, I've organized this regulatory ... 阅读全帖 |
|
O**I
发帖数: 776 | 45 http://www.thestreet.com/story/10944267/1/biotech-calendar-fda-
BOSTON (TheStreet) -- An early Christmas present for biotech investors: The
first (overstuffed) FDA drug approval calendar of 2011.
More from Adam Feuerstein
Dendreon Bringing Provenge to EuropeBiotech Stock Mailbag: Best Stocks to
Watch in '11Merck Beats Vertex to FDA Hep C Filing
Market Activity
Orexigen Therapeutics Inc.| OREX
DOWN
Dendreon Corporation| DNDN
InterMune Inc.| ITMN
For easy reference, I've organized this regulatory ... 阅读全帖 |
|
f**********g
发帖数: 2252 | 46 http://www.thestreet.com/_yahoo/story/10989791/1/biotech-calend
By Adam Feuerstein 01/31/11 - 09:10 AM EST
ALIM, AEN, EXEL, PLX, GENZ, IDIX, AVNR
BOSTON, Mass. (TheStreet) -- A calendar of important, potentially stock-
moving biotech events for February:
More from Adam Feuerstein
NPS Pharma: Gattex Bowel Study SucceedsArena Pharma: Weight-Loss Drug
WoesBiotech Stock Mailbag: Orexigen TherapeuticsMarket Activity
AVANIR Pharmaceuticals| AVNR DOWNAlimera Sciences Inc.| ALIM DOWNProtalix
BioThera... 阅读全帖 |
|
f**********g
发帖数: 2252 | 47 http://www.thestreet.com/_yahoo/story/10989791/1/biotech-calend
By Adam Feuerstein 01/31/11 - 09:10 AM EST
ALIM, AEN, EXEL, PLX, GENZ, IDIX, AVNR
BOSTON, Mass. (TheStreet) -- A calendar of important, potentially stock-
moving biotech events for February:
More from Adam Feuerstein
NPS Pharma: Gattex Bowel Study SucceedsArena Pharma: Weight-Loss Drug
WoesBiotech Stock Mailbag: Orexigen TherapeuticsMarket Activity
AVANIR Pharmaceuticals| AVNR DOWNAlimera Sciences Inc.| ALIM DOWNProtalix
BioThera... 阅读全帖 |
|
w*******0
发帖数: 13 | 48 BOSTON (TheStreet) -- An early Christmas present for biotech investors: The
first (overstuffed) FDA drug approval calendar of 2011.
For easy reference, I've organized this regulatory calendar in chronological
order based on the drug approval decision date. I've also included
information on pending FDA advisory panels. At the end of the calendar is a
list of companies with potential regulatory milestones in 2011 based on
expected but not yet completed drug approval filings.
In all, this calendar ... 阅读全帖 |
|
w*******0
发帖数: 13 | 49 BOSTON (TheStreet) -- An early Christmas present for biotech investors: The
first (overstuffed) FDA drug approval calendar of 2011.
For easy reference, I've organized this regulatory calendar in chronological
order based on the drug approval decision date. I've also included
information on pending FDA advisory panels. At the end of the calendar is a
list of companies with potential regulatory milestones in 2011 based on
expected but not yet completed drug approval filings.
In all, this calendar ... 阅读全帖 |
|
y*****l
发帖数: 5997 | 50 http://www.thestreet.com/story/11016605/1/biotech-calendars-201
By Adam Feuerstein 02/22/11 - 07:36 AM ES
Stock quotes in this article:HGSI, OPTR, XNPT, SPPI, DRRX, PATH
BOSTON (TheStreet) -- I've updated the 2011 FDA drug approval calendar.
For easy reference, I've organized this regulatory calendar in chronological
order based on the drug approval decision date. I've also included
information on pending FDA advisory panels. At the end of the calendar is a
list of companies with potential regul... 阅读全帖 |
|
